Investigating Derivatives of Tanshinone IIA Sulfonate Sodium and Chloroxine for Their Inhibition Activities against the SARS-CoV‑2 Papain-like Protease

• Published in: ACS omega Vol. 7; no. 51; pp. 48416 - 48426
• Main Authors: Chen, Xin, Chen, Ke, Zhang, Zhaoyong, Wei, Peilan, Zhang, Lu, Xu, Yunxia, Lun, Qili, Ma, Yanhong, Wu, Fang, Zhang, Ying, Wang, Yanqun, Zhao, Jincun, Zhou, Yaoqi, Zhan, Jian, Xu, Wei
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 27-12-2022
• ISSN: 2470-1343; 2470-1343
• DOI: 10.1021/acsomega.2c06675

SARS-CoV-2 has caused a global pandemic of COVID-19, posing a huge threat to public health. The SARS-CoV-2 papain-like cysteine protease (PLpro) plays a significant role in virus replication and host immune regulation, which is a promising antiviral drug target. Several potential inhibitors have been identified in vitro. However, the detailed mechanism of action and structure–activity relationship require further studies. Here, we investigated the structure–activity relationships of the series of derivatives of tanshinone IIA sulfonate sodium (TSS) and chloroxine based on biochemical analysis and molecular dynamics simulation. We found that compound 7, a derivative of chloroxine, can disrupt PLpro-ISG15 interaction and exhibits an antiviral effect for SARS-CoV-2 variants (wild type, delta, and omicron) at the low micromolar level. These studies confirmed that inhibiting PLpro-ISG15 interaction and, thus, restoring the host’s innate immunity are effective methods for fighting against viral infection.